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Background and Purpose To compare the efficacy and safety of antiplatelet agents for the secondary 
prevention of ischemic stroke based on cytochrome P450 2C19 (CYP2C19) polymorphisms.
Methods This study was a prospective, multicenter, randomized, parallel-group, open-label, blind 
genotype trial. First time non-cardiogenic ischemic stroke patients were enrolled and screened 
within 30 days. Participants were randomized to receive either triflusal or clopidogrel for secondary 
stroke prevention. The primary outcome was the time from randomization to first recurrent 
ischemic stroke or hemorrhagic stroke.
Results The required sample size was 1,080 but only 784 (73%) participants were recruited. In 
patients with a poor CYP2C19 genotype for clopidogrel metabolism (n=484), the risk of recurrent 
stroke among those who received triflusal treatment was 2.9% per year, which was not 
significantly different from those who received clopidogrel treatment (2.2% per year; hazard ratio 
[HR], 1.23; 95% confidence interval [CI], 0.60–2.53). In the clopidogrel treatment group (n=393), 
38% had good genotypes and 62% poor genotypes for clopidogrel metabolism. The risk of 
recurrent stroke in patients with a good CYP2C19 genotype was 1.6% per year, which was not 
Correspondence: Kyung-Yul Lee
Department of Neurology, Gangnam 
Severance Hospital, 
Yonsei University College of Medicine, 
211 Eonju-ro, Gangnam-gu, 
Seoul 06273, Korea
Tel: +82-2-2019-3325
Fax: +82-2-3462-5904 
E-mail: kylee@yuhs.ac
Received: June 20, 2017
Revised: August 17, 2017
Accepted: August 18, 2017
This study was funded by MyungIn 
Pharmaceuticals, which had no role in 
the trial design, data collection, analysis, 
interpretation, or writing of the report. 
The corresponding author reviewed the 
trial report, had full access to all study 
data, and took final responsibility for the 
decision to submit the work for 
publication. All other authors were 
investigators who had full access to the 
data. 
The authors have no financial conflicts 
of interest.
Vol. 19 / No. 3 / September 2017
https://doi.org/10.5853/jos.2017.01249 http://j-stroke.org 357
Introduction
In the absence of an effective secondary prevention strategy, 
patients with ischemic stroke (IS) have a high probability (4–
16% per year) of experiencing a second atherosclerotic vascu-
lar event.1 Oral antiplatelet therapy is a widely used secondary 
prevention strategy for non-cardiogenic IS.2,3 However, several 
studies have shown that platelet inhibition by clopidogrel ex-
hibits patient-to-patient variability.4 Factors associated with 
clopidogrel response variability include clinical and genetic 
variables, as well as drug interactions. The hepatic cytochrome 
P450 (CYP) enzymatic system metabolizes approximately 80% 
of all clinical drugs, and is required for the bioactivation of 
clopidogrel; CYP2C19 generates an active oxidized metabolite 
of clopidogrel that exerts antiplatelet activity by inhibiting 
P2Y12 receptors.5 Though numerous studies have demonstrat-
ed an association between clopidogrel resistance and adverse 
ischemic events, this phenomenon has yet to be confirmed in a 
large-scale trial.
For the secondary prevention of IS, triflusal has a comparable 
antiplatelet effect to aspirin and offers a lower risk of bleed-
ing.6,7 Triflusal does not require oxidation by the hepatic CYP 
system for the generation of active metabolites; rather, triflusal 
is deacetylated during hepatic first-pass metabolism to form 
2-OH-4-trifluoromethyl benzoic acid. This metabolite irrevers-
ibly inhibits cyclooxygenase-1 (COX-1) and reduces the pro-
duction of thromboxane B2 (TXB2).2
No clinical study to date has evaluated the relationship be-
tween stroke recurrence during secondary prevention of IS and 
CYP2C19 genotype status. Accordingly, the Comparison of Tri-
flusal and Clopidogrel Effects in Secondary Prevention of stroke 
based on cytochrome P450 2C19 genotyping (MAESTRO) study 
was designed to compare the efficacy and safety of antiplate-
let agents for the secondary prevention of IS based on CY-
P2C19 polymorphisms.
Methods 
Study design and participants 
The MAESTRO study methods have been published previously.8 
This study was a prospective, multicenter, randomized, parallel-
group, open-label, blind genotype trial conducted at 18 tertia-
ry-care hospitals in South Korea, between March 15, 2010 and 
December 31, 2014. Participants were eligible if they were 20 
years of age or older and had their first time non-cardiogenic 
IS within 30 days prior to screening. Non-cardiogenic IS was 
classified according to the Trial of ORG 10172 in the Acute 
Stroke Treatment (TOAST) classification system. The main ex-
clusion criteria were: contraindications to trial drugs, a high-
risk potential of cardiac source of embolism, any non-athero-
sclerotic vasculopathies, use of anticoagulants or two or more 
antiplatelet agents, congestive heart failure, impaired renal or 
hepatic function, anemia or thrombocytopenia, bleeding dia-
thesis or cancer, and pregnancy or lactation.8 The study proto-
col was approved by the institutional review board of each 
participating hospital. All patients provided written informed 
consent prior to study participation.
Randomization and masking
Eligible participants were randomized in a 1:1 ratio to either 
the triflusal group or clopidogrel group. Randomization was 
stratified by clinical site via random permuted blocks in sizes of 
four or six. Each screen-eligible participant was randomly as-
signed through a secure web-based registration system with 
telephone back-up. The study had an open-label design; both 
the investigator and patient were aware of the study drug, but 
genotype data were masked until the end of the trial.
Procedures 
During the trial, participants received either 300 mg triflusal 
twice per day (600 mg/day) or 75 mg clopidogrel once daily. 
Initial loading of the study drug, proton pump inhibitor, and 
use of a concomitant antiplatelet or anticoagulant drug were 
strictly prohibited. All patients received appropriate medical 
treatment at the discretion of the attending neurologist, in-
cluding anti-hypertensive and/or statin treatment, and rigorous 
control of other vascular risk factors.8 
CYP2C19 genotype status was assessed using the Seeplex 
CYP2C19 ACE genotyping system (Seegene, Seoul, Korea) and 
Real-Q CYP2C19 genotyping kit (Biosewoom, Seoul, Korea). The 
significantly different from those with a poor genotype (2.2% per year; HR, 0.69; 95% CI, 0.26–1.79).
Conclusions Whilst there were no significant differences between the treatment groups in the rates of stroke recurrence, major vascular 
events, or coronary revascularization, the efficacy of antiplatelet agents for the secondary prevention of stroke according to CYP2C19 
genotype status remains unclear.
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major alleles of the CYP2C19 gene are *1, *2, *3, and *17, and 
about 55% of Asians and 30% of Caucasians have a loss-of-
function mutation in one or more alleles (*2 or *3).9 The See-
plex CYP2C19 ACE Genotyping system identified two single 
nucleotide polymorphisms (*2, *3 alleles) and the Real-Q CY-
P2C19 genotyping kit detected the *17 polymorphism. Each 
participant was classified as an ultrarapid metabolizer (UM: 
*1/*17, *17/*17), extensive metabolizer (EM: *1/*1), intermedi-
ate/unknown metabolizer (*1/*2, *1/*3 and *2/*17, *3/*17), or 
poor metabolizer (PM: *2/*2, *2/*3, *3/*3) based on their CY-
P2C19 genotype status. UM or EM status patients were allo-
cated into the good genotype group for clopidogrel metabo-
lism, and intermediate/unknown metabolizer, or PM status pa-
tients, were allocated into the poor genotype group.
Outcome measures 
The primary outcome was the time from randomization to first 
recurrent IS or hemorrhagic stroke. Evidence of stroke included: 
a) symptoms lasting more than 24 hours, or b) symptoms com-
pletely resolved within 24 hours based on neuroimaging in the 
clinically relevant brain area. There were three pre-specified 
secondary outcomes: 1) time to first IS, 2) time to first myocar-
dial infarction (MI) or coronary revascularization, and 3) time 
to first major vascular event (i.e., stroke, MI, or vascular death). 
All suspected outcomes were adjudicated by the Central Inde-
pendent Adjudication Committee, based on anonymized writ-
ten descriptions of the outcome event and ancillary investiga-
tions. The committee was masked to treatment allocation. 
Safety was evaluated by regular examination and laboratory 
testing after enrolment throughout the study. An independent 
data safety monitoring committee evaluated adverse drug 
events, and reviewed the safety of the study.
Statistical analysis 
Direct comparison studies were not available to support a 
comparison of triflusal and clopidogrel monotherapy. Based on 
the TACIP study, an annual stroke recurrence rate of 3.85% 
was expected in the triflusal treatment group.10 According to 
the PRoFESS trial, an annual stroke recurrence rate of 3.52% 
was expected in the clopidogrel treatment group.11 Among 
clopidogrel-treated patients in the TRITON-TIMI 38 study, in-
creased risk of stroke was observed in patients carrying a CY-
P2C19 reduced-function allele compared with non-carriers 
(0.88% vs. 0.24%; hazard ratio [HR], 3.93; 95% confidence in-
terval [CI], 0.66–23.51).12 Based on these results, this study as-
sumed an annual stroke recurrence rate of 7.74% in the clopi-
dogrel group and 3.85% in the triflusal group in patients allo-
cated to the poor genotype group for clopidogrel metabolism. 
Thus, at least 594 participants with a poor genotype were re-
quired for the primary analysis based on a log-rank test to de-
tect a 50% risk reduction in the triflusal group with 80% pow-
er, a two-sided type I error of 5.0%, a recruitment period of 
two years, a minimum follow-up period of 24 months, and a 
discontinuation rate of 20%. Based on a report indicating that 
55% of Korean participants belong to the poor genotype 
group,13 the required sample size was 1,080. 
Efficacy analyses were performed on both modified inten-
tion-to-treat (mITT) and the per-protocol (PP) populations. The 
mITT population included patients who had taken at least one 
dose of the study drug after randomization. The PP population 
included patients who completed the study schedule without a 
protocol violation and had >80% medication adherence. Safety 
analyses were performed on the mITT population. Cumulative 
incidences of primary and secondary outcomes were estimated 
by the Kaplan-Meier method, and differences between groups 
were assessed using log-rank tests. Cox proportional-hazards 
models were used to calculate hazard ratios. Subgroup analy-
ses were performed to test whether CYP2C19 polymorphisms 
were associated with the primary outcome in the treatment 
group. Statistical analyses were performed with SAS version 
9.4 (SAS Institute, Cary, NC, USA).
Results 
Patient characteristics 
The required study sample size was 1,080; however, only 784 
participants (73%) were recruited during the trial, despite a 
one-year study period extension to accommodate slow enrol-
ment. Between March 2010 and December 2012, a total of 
2,875 patients were assessed; 795 participants met the inclu-
sion criteria and underwent randomization. Of these, 784 
(99%) received at least one dose of the trial drug and were in-
cluded in the mITT population, and 597 (76%) completed the 
trial and were included in the PP population (Figure 1). The 
median duration of follow-up was 2.7 years (range, 0–4.7). The 
numbers of withdrawals were similar between the two groups. 
Table 1 summarizes the baseline characteristics of enrolled pa-
tients. The mean age was 61 years, and 32% of participants 
were women. Sixty-one percent of participants had a history of 
hypertension, 29% had diabetes, 28% had dyslipidemia, and 
40% were current tobacco smokers. The median time from 
qualifying stroke to randomization was 8 days, and 76% of pa-
tients were randomized within 14 days. There were no signifi-
cant differences in the times from qualifying stroke to random-
ization between the treatment groups. Brain MRI and diffu-
sion-weighted imaging were performed in 98% of patients. All 
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patients completed at least one vascular imaging study (86% 
magnetic resonance angiography, 28% computed tomography 
angiography, and 4% cerebral angiography). The most frequent 
stroke subtype was lacunar infarction, which occurred in 52% 
of the population, followed by stroke of undetermined etiology 
in 27% of the population, and large artery atherosclerosis in 
21% of the population (Table 1). During follow-up, 86% of pa-
tients were taking a statin and 69% were taking an anti-hy-
Table 1. Baseline demographic and clinical characteristics of participants
Total (n=784)
Good genotype (n=300, 38%) Poor genotype (n=484, 62%)
Triflusal (n=151) Clopidogrel (n=149) Triflusal (n=240) Clopidogrel (n=244)
Age (years) 61.0 (10.7) 60.1 (10.3) 60.7 (10.6) 61.6 (10.5) 61.2 (11.1)
Female gender 252 (32) 45 (30) 46 (31) 76 (32) 85 (35)
Hypertension 476 (61) 100 (66) 80 (54) 146 (61) 150 (61)
Diabetes mellitus 228 (29) 49 (32) 33 (22) 75 (31) 71 (29)
Hypercholesterolemia 223 (28) 39 (26) 37 (25) 75 (31) 72 (30)
Ischemic heart disease 18 (2) 4 (3) 5 (3) 2 (0.8) 7 (3)
Current tobacco smoker 315 (40) 66 (44) 56 (38) 94 (39) 99 (41)
Type of ischemic stroke
LAA 165 (21) 29 (19) 36 (24) 50 (21) 50 (21)
  Lacune 411 (52) 76 (50) 71 (48) 124 (52) 140 (57)
  SUD 208 (27) 46 (31) 42 (28) 66 (27) 54 (22)
Time to randomization (days) 10.5 (6.9) 10.7 (5.4) 10.9 (7.1) 10.1 (7.9) 10.5 (6.1)
Use of antihypertensive at any follow-up visit 540 (69) 114 (75) 96 (64) 173 (72) 157 (64)
Use of statin at any follow-up visit 674 (86) 129 (85) 127 (85) 207 (86) 211 (86)
Values are presented as number (%) of participants, or mean (standard deviation). 
LAA, large artery atherosclerosis; SUD, stroke of undetermined aetiology.
Figure 1. Design of the MAESTRO study. MAESTRO, stroke based on cytochrome P450 2C19 genotyping. *Withdrawal of consent before genotyping.
  2,875 patients assessed for eligibility
795  enrolled and randomly allocated
2,080 ineligible
397 assigned to triusal
6 excluded* 5 excluded*
398 assigned to clopidogrel
391 received treatment
81 withdrawn
 16 adverse events
   3 non-compliance with protocol
 59 withdrawal of consent
   3 transient ischemic attack
106 withdrawn
 19 adverse events
 17 non-compliance with protocol
 65 withdrawal of consent
   5 transient ischemic attack
393 received treatment
285 completed treatment 312 completed treatment
391 included in full 
analysis set and safety
analyses
393 included in full
analysis set and safety
analyses
Han, et al.  Secondary Stroke Prevention and CYP2C19 Genotype
https://doi.org/10.5853/jos.2017.01249360 http://j-stroke.org
pertensive drug.
Clinical outcomes 
Within the poor genotype group for clopidogrel metabolism 
(484 participants), there were no statistically significant differ-
ences in baseline characteristics according to treatment group. 
Thirty (6.2%) had recurrent stroke: 25 (83%) experienced an IS 
and 5 (17%) experienced an intracerebral hemorrhage (ICH). 
The risk of recurrent stroke among patients assigned to the tri-
flusal treatment group was 2.9% per year, and was not signifi-
cantly different from that among patients assigned to the 
clopidogrel treatment group (2.2% per year; HR, 1.23; 95% CI, 
0.60–2.53; Table 2 and Figure 2). There was no significant dif-
ference in the reduction of recurrent IS risk according to treat-
ment group (HR, 1.37; 95% CI, 0.62–3.01). In the triflusal 
treatment group, there was no significant reduction in the risk 
of a major vascular event (HR, 1.23; 95% CI, 0.61–2.45). More-
over, no difference in all-cause mortality was observed be-
tween treatment groups (HR, 1.11; 95% CI, 0.22–5.49). Finally, 
there was no heterogeneity of treatment effect on the primary 
outcome, according to age, sex, smoking, stroke subtype, or 
between the pre-specified subgroups (P>0.05 for all compari-
sons; Supplementary Figure 1).
Of 393 participants in the clopidogrel treatment group, 149 
(38%) were assigned to the good genotype group and 244 
(62%) were assigned to the poor genotype group for clopido-
grel metabolism. There were no statistically significant differ-
ences in baseline characteristics according to genotype group 
(Table 1). A total of 20 (5.1%) patients had a recurrent stroke: 
15 (75%) experienced an IS and 5 (25%) experienced an ICH. 
The risk of recurrent stroke among patients in the good geno-
type group was 1.6% per year and was not significantly differ-
ent from that among patients in the poor genotype group 
(2.2% per year; HR, 0.69; 95% CI, 0.26–1.79) (Table 3 and Fig-
ure 2). In the good genotype group, there was a non-signifi-
cant 41% decrease in the relative risk of recurrent IS (HR, 0.59, 
95% CI, 0.19–1.85), and no significant reduction in the risk of 
Table 2. Efficacy outcomes in the poor genotype group*
Outcome
Triflusal (n=240) Clopidogrel (n=244)
Hazard ratio (95% CI) P
n Rate (%/yr) n Rate (%/yr)
All strokes (ischemic and hemorrhagic) 16 2.9 14 2.2 1.23 (0.60–2.53) 0.565
Ischemic stroke 14 2.5 11 1.7 1.37 (0.62–3.01) 0.435
Intracerebral hemorrhage 2 0.4 3 0.5 0.74 (0.12–4.41) 0.737
Myocardial infarction or coronary revascularization 1 0.2 2 0.3 0.56 (0.05–6.13) 0.627
Myocardial infarction 1 0.2 1 0.16 1.11 (0.07–17.67) 0.944
Coronary revascularization 0 0 1 0.16 - -
Major vascular events† 17 3.0 15 2.4 1.23 (0.61–2.45) 0.566
All deaths 3 0.5 3 0.5 1.11 (0.22–5.49) 0.900
Vascular causes 0 0 0 0 - -
Nonvascular causes 3 0.5 3 0.5 1.11 (0.22–5.49) 0.900
CI, confidence interval.
*A time-to-first-event model was used for each outcome category; rates are annualized. The total number of patient-years of exposure for the primary out-
come measure (all strokes) was 559 for patients in the triflusal treatment group and 637 for those in the clopidogrel treatment group; †Major vascular events 
included stroke, myocardial infarction, and vascular death.
Figure 2. Differences in the primary endpoint according to CYP2C19 geno-
type and treatment. CYP2C19, cytochrome P450 2C19; CI, confidence in-
terval.
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a major vascular event (HR, 0.64; 95% CI, 0.25–1.66). Sub-
group analyses showed that there was a significant treatment-
by-subgroup interaction for sex in patients randomized to the 
clopidogrel group based on genotype (P=0.027). There was a 
trend towards a reduction in risk for the primary outcome in 
men in the good genotype group, whilst women in the good 
genotype group showed an increased risk for the primary out-
come (Supplementary Figure 2). 
The most frequent genotype in the entire study population 
was intermediate metabolizer (348, 45%), followed by EM 
(291, 37%), PM (126, 16%), unknown (10, 1%), and UM (9, 
1%). These results are consistent with previous findings.13 There 
were also no significant differences in stroke recurrence, major 
vascular events, or coronary revascularization regarding treat-
ment and genotype (Table 4).
The PP analysis, which included 285 patients from the triflu-
sal treatment group and 312 patients from the clopidogrel 
treatment group, showed results consistent with those above. 
Of 386 participants in the poor genotype group, 8.2% had a 
recurrent stroke. The risk of recurrent stroke among patients 
assigned to the triflusal treatment group was 3.2% per year, 
and was not significantly different from that among patients 
Table 4. Efficacy outcomes according to treatment and genotype
Total (n=784) 
Good genotype (n=300, 38%) Poor genotype (n=484, 62%) 
UM (n=9, 1%) EM (n=291, 37%) IM (n=348, 45%) PM (n=126, 16%) Unknown (n=10, 1%) 
Triflusal 391 (50) 4 (1) 147 (38) 173 (44) 61 (16) 6 (1)
All strokes (ischemic and hemorrhagic) 26 (6.6) 0 (0) 10 (6.8) 12 (6.9) 4 (6.6) 0 (0)
Ischemic stroke 24 (6.1) 0 (0) 10 (6.8) 10 (5.8) 4 (6.6) 0 (0)
Intracerebral hemorrhage 2 (0.5) 0 (0) 0 (0) 2 (1.1) 0 (0) 0 (0)
Myocardial infarction or coronary
  revascularization
3 (0.8) 0 (0) 1 (0.7) 1 (0.6) 1 (1.6) 0 (0)
Clopidogrel 393 (50) 5 (1) 144 (37) 175 (44) 65 (17) 4 (1)
All strokes (ischemic and hemorrhagic) 20 (5.1) 0 (0) 6 (4.2) 10 (5.7) 4 (6.2) 0 (0)
Ischemic stroke 15 (3.8) 0 (0) 4 (2.8) 7 (4.0) 4 (6.2) 0 (0)
Intracerebral hemorrhage 5 (1.3) 0 (0) 2 (1.4) 3 (1.7) 0 (0) 0 (0)
Myocardial infarction or coronary
  revascularization
3 (0.8) 0 (0) 1 (0.7) 2 (1.1) 0 (0) 0 (0) 
Values are presented as number (%) of total participants in the treatment group. 
UM, ultrarapid metabolizer; EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer.
Table 3. Efficacy outcomes in the clopidogrel treatment group according to genotype*
Outcome
Good genotype (n=149) Poor genotype (n=244)
Hazard ratio (95% CI) P
n Rate (%/yr) n Rate (%/yr)
All strokes (ischemic and hemorrhagic) 6 1.6 14 2.2 0.69 (0.26–1.79) 0.443
Ischemic stroke 4 1.1 11 1.7 0.59 (0.19–1.85) 0.357
Intracerebral hemorrhage 2 0.5 3 0.5 1.06 (0.18–6.33) 0.951
Myocardial infarction or coronary revascularization 1 0.3 2 0.3 0.81 (0.07–8.95) 0.865
Myocardial infarction 0 0 1 0.16 - -
Coronary revascularization 1 0.3 1 0.16 1.62 (0.10–25.88) 0.731
Major vascular events† 6 1.6 15 2.4 0.64 (0.25–1.66) 0.358
All deaths 2 0.5 3 0.5 1.09 (0.18–6.54) 0.923
Vascular causes 0 0 0 0 - -
Nonvascular causes 2 0.5 3 0.5 1.09 (0.18–6.54) 0.923
CI, confidence interval.
*A time-to-first-event model was used for each outcome category; rates are annualized. The total number of patient years of exposure for the primary out-
come measure (all strokes) in the clopidogrel treatment group was 380 for patients with a good genotype and 637 for those with a poor genotype; †Major 
vascular events included stroke, myocardial infarction, and vascular death.
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assigned to the clopidogrel treatment group (2.3% per year; 
HR, 1.33; 95% CI, 0.65–2.71). In the clopidogrel treatment 
group, 117 participants (38%) were assigned to the good geno-
type group and 195 (62%) were assigned to the poor genotype 
group for clopidogrel metabolism. Of participants in the clopi-
dogrel treatment group, 20 (6.4%) had a recurrent stroke. The 
risk of recurrent stroke among patients in the good genotype 
group was 1.7% per year, and was not significantly different 
from that among patients in the poor genotype group (2.3% 
per year; HR, 0.71; 95% CI, 0.27–1.86).
Safety 
During follow-up, there were no significant differences in the 
hemorrhage rates between the treatment groups (Table 5). In 
the poor genotype group, the rates of all types of hemorrhages 
were 2.1% per year in the triflusal treatment group, and 2.2% 
per year in the clopidogrel treatment group (HR, 0.97; 95% CI, 
0.48–2.24). In the clopidogrel treatment group, the rates of all 
types of hemorrhages were 3.3% per year in the good geno-
type group and 2.2% per year in the poor genotype group (HR, 
1.66; 95% CI, 0.78–3.55).
Discussion 
Despite an extended enrolment period, this trial failed to meet 
its recruitment goal due to slow enrolment, and was therefore 
discontinued. The main reason for this may have been that 
many investigators did not enroll patients with severe athero-
sclerotic changes, but instead elected to implement early ag-
gressive dual antiplatelet therapy. Therefore, about half of the 
enrolled patients had lacunar infarction. Prior to the MAESTRO 
trial, no direct comparison study had addressed the relation-
ship between CYP2C19 polymorphisms and stroke recurrence 
during secondary prevention of IS.14 Since the initiation of the 
MAESTRO trial, the SPS3 trial subgroup analysis identified sig-
nificant differences in stroke recurrence according to CYP2C19 
genotype-inferred metabolizer status in white subcortical 
stroke patients receiving aspirin and clopidogrel.15 Notably, no 
significant differences were observed when patients from all 
race groups were combined. The recent CHANCE trial sub-
study demonstrated that the use of clopidogrel plus aspirin, 
compared with aspirin alone, reduced the risk of first-time 
stroke in a subgroup of patients who were not carriers of a CY-
P2C19 loss-of-function allele.16 In this trial, stroke occurred in 
8.2% of patients in the clopidogrel-aspirin group and 11.7% of 
those in the aspirin group. However, this study was performed 
exclusively among Chinese patients with minor IS or transient 
ischemic attack.17 Only 42% of patients were receiving lipid-
lowering agents, 35% were receiving anti-hypertensive drugs, 
and 25% were receiving a form of traditional Chinese medi-
cine.18 During the SPS3 trial, the risk of recurrent stroke was 
2.7% per year among participants taking aspirin and 2.5% per 
year among those taking aspirin and clopidogrel dual therapy; 
however, 85% of patients in this trial were also using a statin.19 
In the present study, we observed a 41% decrease in the rel-
ative risk of recurrent IS in the good CYP2C19 genotype group 
for clopidogrel metabolism, yet with a wide 95% CI in the 
clopidogrel treatment group. Similarly, several clinical trials in 
coronary artery disease have failed to demonstrate associations 
between CYP2C19 polymorphisms and clinical outcomes.20,21 In 
the TRILOGY ACS trial, CYP2C19 functional variants were not 
successfully associated with the composite outcome of cardio-
vascular death, MI, or stroke.22 The results of our study may be 
inconclusive but, in an ad hoc manner, we calculated a condi-
tional power (CP), or the chance of obtaining a statistically sig-
nificant result at the end of the trial given the data so far. Even 
if the MEASTRO study was not prematurely stopped, the CP for 
obtaining a significant effect for CYP2C19 genotype was as 
low as 4.2%. Thus, it can be hypothesized that the findings ob-
served in the CHANCE trial are not easily replicated in popula-
Table 5. Safety outcomes
Total (n=784)
Good genotype Poor genotype 
Triflusal (n=151) Clopidogrel (n=149) Triflusal (n=240) Clopidogrel (n=244)
All hemorrhages 49 (6.3) 10 (6.6) 13 (8.7) 12 (5.0) 14 (5.7)
Intracranial hemorrhages 10 (1.3) 0 (0) 4 (2.7) 3 (1.3) 3 (1.2)
Intracerebral 7 (0.9) 0 (0) 2 (1.3) 2 (0.8) 3 (1.2)
Subdural or epidural 3 (0.4) 0 (0) 2 (1.3) 1 (0.4) 0 (0)
Extracranial bleeding 39 (5.0) 10 (6.6) 9 (6.0) 9 (3.8) 11 (4.5)
Gastrointestinal 22 (2.8) 5 (3.3) 3 (2.0) 8 (3.3) 6 (2.5)
Other 17 (2.2) 5 (3.3) 6 (4.0) 1 (0.4) 5 (2.0)
Values are presented as number (%) of participants.
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tions with a higher adherence to risk factor control. 
We found an unexpected interaction between sex and clopi-
dogrel treatment among patients in the good genotype group. 
Men receiving clopidogrel treatment in the good genotype 
group showed a trend toward reduced risk for the primary out-
come. Ex vivo studies have demonstrated that women are more 
often hyporesponsive to clopidogrel than men; however, the 
clinical implications and validity of this observation remain un-
certain.23 A recent meta-analysis showed evidence of similar 
gender-related benefits (major cardiovascular events, MI, or 
stroke) and risks (major bleeding) in vascular disease; the ran-
dom-effect estimates ratio of relative risks (rRR) across studies 
was not statistically different according to male sex (rRR, 0.97; 
95% CI, 0.90–1.04).24 Further multinational pragmatic trials 
may be essential for exploring alternative predictors of re-
sponse to P2Y12 receptor inhibitor therapy with respect to 
baseline risk factors, ethnicity, or prior disease.
There were several limitations to this study, particularly sam-
ple size calculation and subsequent recruitment. We could not 
refer to a previous clinical trial on stroke recurrence according 
to CYP2C19 genotype status during clopidogrel therapy. We 
used the results from the TRITON-TIMI 38 and PRoFESS studies 
to calculate annual stroke recurrence, but a low stroke rate in 
TRITON-TIMI 38 study resulted in a large HR and wide CI for 
stroke in the poor genotype group (HR, 3.93; 95% CI, 0.66–
23.51). Second, the actual annual rate of stroke recurrence ob-
served in our study was less than one third of the anticipated 
value according to our study design. A low stroke rate may 
have been related to the use of statins and anti-hypertensive 
drugs by the majority of included participants, which was simi-
lar to the rates in other recent studies for the prevention of re-
current stroke.19 Third, the effect of antiplatelet agents may 
vary according to ischemic stroke subtype; in this trial, 52% of 
participants had lacunar infarction, which may have been of 
pure atherothrombotic origin.25 Finally, this trial enrolled only 
Korean patients, limiting the generalizability of our findings to 
other geographic regions. These limitations should be consid-
ered during the interpretation of our data.
Conclusions 
There were no differences in stroke recurrence, major vascular 
events, or coronary revascularization between triflusal and 
clopidogrel therapy in patients with a poor genotype for clopi-
dogrel metabolism. While we observed a non-significant 41% 
decrease in relative risk of recurrent IS associated with a good 
clopidogrel metabolism genotype, our study was not suffi-
ciently powered to detect a statistically significant difference. 
The results of this study were inconclusive in terms of anti-
platelet agent efficacy for the secondary prevention of stroke 
according to CYP2C19 genotype status. Genes have been found 
to alter patient responses to pharmacological agents and influ-
ence clinical disease outcomes but, currently, there are no 
standardized treatment recommendations for patients with 
CYP2C19 genotypes associated with poor clopidogrel metabo-
lism.26,27 Our findings support the need for additional efficacy 
and safety data to enable physicians to make individual treat-
ment decisions for the secondary prevention of stroke.
Supplementary materials 
Supplementary materials related to this article can be found 
online at https://doi.org/10.5853/jos.2017.01249.
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Supplementary Figure 1. Hazard ratios for the primary outcome in subgroups of participants with a poor genotype for clopidogrel metabolism. CI, confi-
dence interval; LAA, large artery atherosclerosis; SUD, stroke of undetermined aetiology. 
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Supplementary Figure 2. Hazard ratios for the primary outcome in subgroups of participants who received clopidogrel treatment. CI, confidence interval; 
TOAST, Trial of ORG 10172 in the Acute Stroke Treatment; LAA, large artery atherosclerosis; SUD, stroke of undetermined aetiology; N/A, not available.
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